Mehmet Sayiner1,2, Maria Stepanova3, Leyla De Avila2, Pegah Golabi2, Andrei Racila2,3, Zobair M Younossi4,5. 1. Department of Medicine, Center for Liver Disease, Inova Fairfax Hospital, Falls Church, VA, USA. 2. Betty and Guy Beatty Center for Integrated Research, Claude Moore Health Education and Research Building, Inova Health System, 3300 Gallows Road, Falls Church, VA, 22042, USA. 3. Center for Outcomes Research in Liver Diseases, Washington, DC, USA. 4. Department of Medicine, Center for Liver Disease, Inova Fairfax Hospital, Falls Church, VA, USA. zobair.younossi@inova.org. 5. Betty and Guy Beatty Center for Integrated Research, Claude Moore Health Education and Research Building, Inova Health System, 3300 Gallows Road, Falls Church, VA, 22042, USA. zobair.younossi@inova.org.
Abstract
BACKGROUND: Primary biliary cholangitis (PBC) is progressive and can cause end-stage liver disease necessitating a liver transplant (LT). PBC patients may be disadvantaged on LT waitlist due to MELD-based priority listing or other factors. AIM: The aim was to assess waitlist duration, waitlist mortality, and post-LT outcomes of PBC patients. METHODS: The Scientific Registry of Transplant Recipients data for 1994-2016 was utilized. Adult patients with PBC without hepatocellular carcinoma (HCC) were selected. Their clinico-demographic parameters and waitlist and post-transplant outcomes were compared to those of patients with hepatitis C (HCV) without HCC. RESULTS: Out of 223,391 listings for LT in 1994-2016, 8133 (3.6%) was for PBC without HCC. Mean age was 55.5 years, 76.9% white, 86.2% female, mean MELD score 21, 6.6% retransplants. There were 52,017 patients with hepatitis C included for comparison. The mean waitlist mortality was 17.9% for PBC and 17.6% for HCV (p > 0.05). The average transplantation rate was 57.7% for PBC and 53.3% for HCV (p < 0.0001), while waitlist dropout (death or removal due to deterioration) rate was 25.0% for PBC and 25.4% for HCV (p > 0.05). There was no significant difference in median waiting duration till transplantation between PBC patients and HCV after 2002 (103 vs. 95 days, p > 0.05). Post-LT mortality and graft loss rates were significantly lower in PBC than in HCV patients (all p < 0.02). CONCLUSIONS: Despite no evidence of impaired waitlist outcomes and favorable post-transplant survival in patients with PBC, there is still a high waitlist dropout rate suggesting the presence of an unmet need for effective treatment.
BACKGROUND:Primary biliary cholangitis (PBC) is progressive and can cause end-stage liver disease necessitating a liver transplant (LT). PBC patients may be disadvantaged on LT waitlist due to MELD-based priority listing or other factors. AIM: The aim was to assess waitlist duration, waitlist mortality, and post-LT outcomes of PBC patients. METHODS: The Scientific Registry of Transplant Recipients data for 1994-2016 was utilized. Adult patients with PBC without hepatocellular carcinoma (HCC) were selected. Their clinico-demographic parameters and waitlist and post-transplant outcomes were compared to those of patients with hepatitis C (HCV) without HCC. RESULTS: Out of 223,391 listings for LT in 1994-2016, 8133 (3.6%) was for PBC without HCC. Mean age was 55.5 years, 76.9% white, 86.2% female, mean MELD score 21, 6.6% retransplants. There were 52,017 patients with hepatitis C included for comparison. The mean waitlist mortality was 17.9% for PBC and 17.6% for HCV (p > 0.05). The average transplantation rate was 57.7% for PBC and 53.3% for HCV (p < 0.0001), while waitlist dropout (death or removal due to deterioration) rate was 25.0% for PBC and 25.4% for HCV (p > 0.05). There was no significant difference in median waiting duration till transplantation between PBC patients and HCV after 2002 (103 vs. 95 days, p > 0.05). Post-LT mortality and graft loss rates were significantly lower in PBC than in HCV patients (all p < 0.02). CONCLUSIONS: Despite no evidence of impaired waitlist outcomes and favorable post-transplant survival in patients with PBC, there is still a high waitlist dropout rate suggesting the presence of an unmet need for effective treatment.
Authors: Jarone Lee; Adam Belanger; John T Doucette; Carmen Stanca; Scott Friedman; Nancy Bach Journal: Clin Gastroenterol Hepatol Date: 2007-09-27 Impact factor: 11.382
Authors: Keith D Lindor; M Eric Gershwin; Raoul Poupon; Marshall Kaplan; Nora V Bergasa; E Jenny Heathcote Journal: Hepatology Date: 2009-07 Impact factor: 17.425
Authors: Mei Lu; Yueren Zhou; Irina V Haller; Robert J Romanelli; Jeffrey J VanWormer; Carla V Rodriguez; Heather Anderson; Joseph A Boscarino; Mark A Schmidt; Yihe G Daida; Amandeep Sahota; Jennifer Vincent; Christopher L Bowlus; Keith Lindor; Talan Zhang; Sheri Trudeau; Jia Li; Loralee B Rupp; Stuart C Gordon Journal: Clin Gastroenterol Hepatol Date: 2017-12-23 Impact factor: 11.382
Authors: P S Kamath; R H Wiesner; M Malinchoc; W Kremers; T M Therneau; C L Kosberg; G D'Amico; E R Dickson; W R Kim Journal: Hepatology Date: 2001-02 Impact factor: 17.425
Authors: Ryan B Perumpail; Robert J Wong; Andy Liu; Channa R Jayasekera; Douglas T Dieterich; Zobair M Younossi; Aijaz Ahmed Journal: Emerg Infect Dis Date: 2016-03 Impact factor: 6.883